Views: 1,940 | Downloads: 60 | Responses: 0

Case ReportOpen Access

131I-Rituximab Treatment in Patient with Relapsed Non-Hodgkin’s Lymphoma: The First Case Report in Thailand

Kositwattanarerk A , Changmuang W , Sangsuriyan J , Thongklam K , Sritara C , Utamakul C , Chamroonrat W , Thamnirat K , Anongpornyochkul Y , Chancharunee S

Abstract | Full Text | References | Citation| Response

Close  
Citation

Kositwattanarerk A, Changmuang W, Sangsuriyan J, Thongklam K, Sritara C, Utamakul C, Chamroonrat W, et al. 131I-Rituximab Treatment in Patient with Relapsed Non-Hodgkin’s Lymphoma: The First Case Report in Thailand. J Med Assoc Thai 2013;96:756.

Radioimmunotherapy (RIT) with 131I-rituximab is a safe and effective treatment in patients with relapsed, refractory follicular lymphoma. The authors demonstrated the first case of 131I-rituximab treatment in the patient with relapsed non-Hodgkin’s lymphoma (NHL) in Thailand. There was no immediate complication after treatment. Impressive treatment response occurred.

Keywords: 131I-rituximab, Non-Hodgkin’s lymphoma, Radioimmunotherapy

Close  
Response

Responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on the jmatonline.com. Although a selection of responses will be included online and in print as readers' letters, their first appearance online means that they are published articles.

Download: PDF